Treatment with Vinorelbine for Relapsed Pleural Mesothelioma

treatment with vinorelbine

A new study suggests that treatment with vinorelbine may boost progression free survival for people with relapsed malignant mesothelioma. Mesothelioma is a virulent cancer caused by exposure to asbestos. Chemotherapy is the primary first-line treatment. But this cancer almost always comes back within a few months.  Now, researchers at the UK’s University of Leicester say treatment with vinorelbine might keep mesothelioma at bay for several months longer. They presented their research at this months’ annual meeting of the American Society of Clinical Oncology.  Second-Line Mesothelioma Treatments Needed Pleural mesothelioma is the most common form of mesothelioma. Tumors grow on the membrane around the lungs. The symptoms often mimic lung cancer but can be even more deadly.  Some of the healthiest … Continue reading Treatment with Vinorelbine for Relapsed Pleural Mesothelioma »

Inflammation Protein May Impact Drug Therapies for Mesothelioma

drug therapies

A protein involved in the inflammatory process could impact how patients respond to drug therapies for mesothelioma. The news comes from researchers at Fox Chase Cancer Center in Philadelphia.  The team led by Joseph Testa, PhD, recently released a study of a protein called RIPK3 and its role in malignant mesothelioma.  Their research showed that people with little or no expression of RIPK3 were less sensitive to drug therapies for mesothelioma. Turning that gene back on might make tumor cells more responsive. The finding could lead to new, more powerful ways to treat this aggressive cancer.  RIPK3, Mesothelioma, and Inflammation Mesothelioma is a rare but fast-growing form of cancer that comes from asbestos exposure. Tumors grow on the tissue that … Continue reading Inflammation Protein May Impact Drug Therapies for Mesothelioma »

Tri-modality Mesothelioma Treatment Triples Survival Time in New Study

tri-modality mesothelioma treatment

A comparison of chemotherapy alone versus surgery-based tri-modality treatment for mesothelioma shows patients who take the more aggressive path tend to live much longer. Malignant pleural mesothelioma is a rare cancer with a poor prognosis. Many patients die within a year of diagnosis. Chemotherapy is the most common treatment. But chemotherapy alone is rarely enough to stop this aggressive cancer. Tri-modality mesothelioma treatment combines several different types of therapies. The goal is to attack mesothelioma from different angles.  Now, a new study suggests that patients who go this route triple their survival over those who choose more conservative treatment. Surgery-Based Tri-Modality Mesothelioma Treatment Pleural mesothelioma is a fast-growing malignancy on the lining around the lungs. It is almost always caused … Continue reading Tri-modality Mesothelioma Treatment Triples Survival Time in New Study »

Paclitaxel May Prevent Metastatic Peritoneal Mesothelioma in High Risk People

metastatic peritoneal mesothelioma

Administering the chemotherapy drug paclitaxel directly into the abdomen of people with mesothelioma might offer a way to prevent metastatic peritoneal mesothelioma. That is the premise of a recent article by Dr. Paul Sugarbaker in the Journal of Gastrointestinal Oncology. Dr. Sugarbaker is a global expert in peritoneal mesothelioma. He works at MedStar Washington Hospital in Washington, DC. Metastatic peritoneal mesothelioma is when mesothelioma cells spread. They move from their original spot to other parts of the abdomen. Paclitaxel can help prevent new tumors in people who already have some metastases. In his new article, Dr. Sugarbaker says the evidence suggests that it might also work to keep metastases from forming. Metastatic Peritoneal Mesothelioma Treatment Malignant mesothelioma is a cancer … Continue reading Paclitaxel May Prevent Metastatic Peritoneal Mesothelioma in High Risk People »

Real-World Mesothelioma Patients Need New Systemic Treatments

real-world mesothelioma patients

The newest study on real-world mesothelioma patients illustrates the need for more ways to treat this devastating cancer.  Many studies focus on a carefully-chosen subset of patients. Patients have to meet specific guidelines to qualify for a mesothelioma clinical trial.  But the authors of a new report in Future Oncology focused on real-world mesothelioma patients in community clinics. The goal was to see what kinds of treatments these patients got and how well they worked.  The results show most people do not have other treatments after first-line therapy. They also suggest that mesothelioma doctors and patients need new first-line alternatives.  First- and Second-Line Mesothelioma Therapies Malignant mesothelioma is the name for cancer on the membranes around internal organs. Pleural mesothelioma … Continue reading Real-World Mesothelioma Patients Need New Systemic Treatments »

Which Mesothelioma Patients will Benefit from Second-Line Chemotherapy

second-line chemotherapy

Japanese oncologists say they have found a way to help predict which peritoneal mesothelioma patients are most likely to get results from second-line chemotherapy. First-line therapy is the mesothelioma treatment that doctors try first. Usually, that is chemotherapy. If that does not work or stops working, they may move on to another option. Second-line chemotherapy is one of those options.  Doctors at National Cancer Center Hospital in Tokyo evaluated mesothelioma cases. These were patients at their institution between 2007 and 2019. They found that patients who have more rounds of first-line chemotherapy are most likely to respond to second-line chemotherapy.  Drug Treatment for Malignant Mesothelioma Peritoneal mesothelioma is a cancer on the lining that surrounds the abdominal organs. It usually … Continue reading Which Mesothelioma Patients will Benefit from Second-Line Chemotherapy »

Phase 3 Clinical Trial to Test Durvalumab for Mesothelioma

phase 3 clinical trial

A potential new first-line immunotherapy treatment for mesothelioma is now recruiting patients for a phase 3 clinical trial. The trial will compare the immunotherapy drug durvalumab (IMFINZI) combined with chemotherapy against chemotherapy alone.  Results from the phase 2 trials of this combination released last year were promising. Tests showed that it extended mesothelioma survival by about 8 months with no debilitating side effects.  The randomized phase 3 clinical trial will try to confirm these results in a larger group of people. Mesothelioma Treatment with Durvalumab Durvalumab is an immune checkpoint inhibitor. Immune checkpoint inhibitors deactivate a cancer cell survival mechanism that helps cancer cells evade the immune system. Pleural mesothelioma and other types of cancer use proteins like PD-1 to … Continue reading Phase 3 Clinical Trial to Test Durvalumab for Mesothelioma »

Chemoresistance in Mesothelioma: The Role of Genetics

chemoresistance in mesothelioma

A team of Swiss and German researchers have a theory about why so many mesothelioma patients experience chemoresistance.  Chemotherapy is the standard first-line treatment for asbestos cancer. But fewer than half of patients respond to it.  The new study suggests that this may have to do with an alteration on the BAP1 gene. Medicine cannot change a person’s underlying genetics. But knowing who is likely to experience chemoresistance could help patients and doctors choose the most effective treatments.  BAP1 Expression and Mesothelioma BAP1 stands for BRCA1 associated protein-1. People who have an inherited mutation of this gene produce less of the BAP1 protein. This seems to increase their risk for malignant mesothelioma and several other conditions. People with BAP1 loss … Continue reading Chemoresistance in Mesothelioma: The Role of Genetics »

Maintenance Therapy with Gemcitabine Extends Mesothelioma Survival in Dutch Study

maintenance therapy

Dutch researchers say administering maintenance therapy with gemcitabine after chemotherapy may help mesothelioma patients live longer than supportive care alone.  Gemcitabine is an antimetabolite sold under the brand name Gemzar. Oncologists use it to treat several other types of cancer. When cancer cells absorb gemcitabine, they can no longer divide into new cancer cells.  Most mesothelioma patients have chemotherapy as their first-line treatment. If they are healthy enough, they may also have mesothelioma surgery. A maintenance therapy is a treatment that follows the main treatment. It is an effort to maintain the effects of the treatment.  The new Dutch study shows gemcitabine may be a safe and effective choice for maintenance therapy. What Does Maintenance Therapy Mean? Right now, there … Continue reading Maintenance Therapy with Gemcitabine Extends Mesothelioma Survival in Dutch Study »

Chemotherapy Resistance in Mesothelioma Patients: New Insights

chemotherapy resistance

Canadian cancer researchers have discovered what may be a key cause of chemotherapy resistance in mesothelioma and other types of cancer. The news could lead to more effective ways of treating malignant mesothelioma.  Chemotherapy resistance is a major problem for mesothelioma patients. The FDA has approved two different drug therapies for mesothelioma. But neither approach seems to hold asbestos cancer at bay long term.  Scientists at Princess Margaret Cancer Centre in Toronto say it may be because cancer cells “hibernate” to escape attack. If doctors can understand this cancer cell defense mechanism, they might be able to undermine it.  The Problem of Chemotherapy Resistance Malignant mesothelioma is the most serious of several illnesses caused by exposure to asbestos. Asbestos fibers … Continue reading Chemotherapy Resistance in Mesothelioma Patients: New Insights »

Get your free copy of
“Surviving Mesothelioma” Today!